Figure 1
Figure 1. 
 Effect of c7E3 Fab (ReoPro) and lamifiban on the activated clotting time of heparinized blood. / Native fresh blood from healthy donors was collected by vein puncture directly in syringes containing 2.5 μg/mL heparin (0.375 U/mL) alone,and 2.5 μg/mL heparin + 20 μg/mL c7E3 Fab, or 2.5 μg/mL heparin +300 nM lamifiban. Two blood samples were collected from each donor, the first on heparin and the second on heparin plus c7E3 Fab or lamifiban. The ACT was determined following the instruction of the manufacturer either in a Hemochron device (A and B) or in a HemoTec device (C and D)using FTK-ACT and HR-ACT cartridges, respectively, containing in both cases kaolin as contact activator. The ACT of each blood sample was measured within 1 minute and then over 45 minutes. Individual data obtained from 4 donors are pooled for each graph.


 Effect of c7E3 Fab (ReoPro) and lamifiban on the activated clotting time of heparinized blood.

Native fresh blood from healthy donors was collected by vein puncture directly in syringes containing 2.5 μg/mL heparin (0.375 U/mL) alone,and 2.5 μg/mL heparin + 20 μg/mL c7E3 Fab, or 2.5 μg/mL heparin +300 nM lamifiban. Two blood samples were collected from each donor, the first on heparin and the second on heparin plus c7E3 Fab or lamifiban. The ACT was determined following the instruction of the manufacturer either in a Hemochron device (A and B) or in a HemoTec device (C and D)using FTK-ACT and HR-ACT cartridges, respectively, containing in both cases kaolin as contact activator. The ACT of each blood sample was measured within 1 minute and then over 45 minutes. Individual data obtained from 4 donors are pooled for each graph.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal